Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company has a price-to-book ratio of 2.28479. The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.